Cambrex $120 Million Investment Includes Increasing Capacity at Charles City Facility 40%
Cambrex has announced a $120 million investment to expand its U.S. API manufacturing operations, specifically increasing capacity at the Charles City facility by 40%.
The company says the expansion supports nearly one million liters of production, enhancing supply chain resilience and providing customers with greater access to locally produced APIs. The Charles City plant, situated on a 45-acre site, manufactures a broad range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.
Thomas Loewald, CEO of Cambrex, said, “The investment in our Charles City facility, the nation’s largest independent API manufacturing site, reflects our commitment to meeting clients’ evolving needs for small molecule and peptide manufacturing.”
The company says Wednesday’s (10.22) commitment builds on Cambrex’s heritage of investing in its drug development and manufacturing network, and follows previous expansions over the past five years, including the addition of highly potent API and large-scale manufacturing capacity in Charles City in 2022.
